Risk factors for venous thrombotic disease

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 610-619

  Rosendaal, F R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN;

ANTITHROMBIN DEFICIENCY; BED REST; BLOOD GROUP; CANCER; CONFERENCE PAPER; GENE MUTATION; HUMAN; HYPERHOMOCYSTEINEMIA; IMMOBILIZATION; INJURY; PREGNANCY; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; PUERPERIUM; RISK ASSESSMENT; RISK FACTOR; SURGERY; VEIN THROMBOSIS;

EID: 0032741802     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615887     Document Type: Conference Paper

References (124)

1. Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 1992;232:155-160.
2. Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forrier A, Dalen JE. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med. 1991;151:933-938.
3. Carter CJ: The natural history and epidemiology of venous thrombosis. Prog Cardiovasc Dis. 1994;36:423-438.
4. Brandjes DP, Büller HR, Heijboer H, Huisman MV, de Rijk M, Jagt H, Ten Cate JW. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet. 1997;349:759-762.
5. Rosendaal FR. Risk factors for venous thrombosis: prevalence, risk and interaction. Semin Hematol. 1997;34:171-187.
6. Greenland S. Applications of stratified analysis methods. In: Rothman KJ, Greenland S, eds. Modern Epidemiology. Philadelphia: Lippincott-Raven; 1998:295-297.
7. Virchow R. Phlogose und Thrombose im Gefäßsystem; Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. Frankfurt: Staatsdruckerei; 1856.
8. White C. An inquiry into the nature and cause of that swelling in one or both of the lower extremities which sometimes happen to in-lying women together with the propriety of drawing the breasts of those who do and also who do not give suck. London: Warrington; 1784.
9. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh. 1965;13:516-530.
10. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453-1457.
11. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348:977-980.
12. Jick H, Derby LE, Wald Myers M, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 1996;348:981-983.
13. Trousseau A. Phlegmasia alba dolens. In: Anonymous Clinique Médicale de l'Hôtel-Dieu de Paris. Paris: J.B. Ballière et fils; 1865:652-695.
14. Bick RL. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost. 1992;18:353-369.
15. Nand S, Messmore H. Hemostasis in malignancy. Am J Hematol. 1990;35:45-55.
16. Donati BM. Cancer and thrombosis: from phlegmasia albans dolens to transgenic mice. Thromb Haemost. 1995;74:278-281.
17. Goldberg RJ, Seneff M, Gore JM, Anderson FA, Greene HL, Wheeler HB, Dalen JE. Occult malignant neoplasms in patients with deep venous thrombosis. Arch Intern Med. 1987;147:251-253.
18. Zurborn KH, Duscha H, Gram J, Bruhn HD. Investigations of coagulation system and fibrinolysis in patients with disseminated adenocarcinomas and non-Hodgkin lymphomas. Oncology. 1990;47:376-380.
19. Monreal M, Fernandez-Llamazares J, Perandreu J, Urrutia A, Sahuquillo JC, Contel E. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost. 1997;78:1316-1318.
20. Prandoni P, Lensing AWA, Büller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, Ten Cate JW. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992;327:1128-1133.
21. Nordström M, Lindblad B, Anderson H, Bergqvist D, Kjellström T. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ. 1994;308:891-894.
22. Coebergh, JWW. Incidence and prognosis of cancer in The Netherlands: studies based on cancer registries. (Thesis) Rotterdam: 1991:191-195.
23. Cohen SH, Ehrlich GE, Kaufman MS, Cope C. Thrombophlebitis following knee surgery. J Bone Joint Surg. 1973;55:106-111.
24. Hull RD, Raskob GE. Prophylaxis of venous thromboembolic disease following hip and knee surgery. J Bone Joint Surg. 1986;68:146-150.
25. Bergqvist D. Frequency of thromboembolic complications. In: Bergquist D, ed. Postoperative Thromboembolism. Berlin, Springer-Verlag, 1983:12-13.
26. Mayo M, Halil T, Browse NL. The incidence of deep vein thrombosis after prostatectomy. Br J Urol. 1971;43:738-742.
27. Walsh JJ, Bonnar J, Wright FW. A study of pulmonary embolism and deep vein thrombosis after major gynaecological surgery using labelled fibrinogen, phlebography and lung scanning. J Obstet Gynaecol Br Commonw. 1974;81:311-316.
28. Hjelmstedt A, Bergvall U. Incidence of thrombosis in patients with tibial fractures. Acta Chir Scand. 1968;134:209-218.
29. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N Engl J Med. 1994;331:1601-1606.
30. Gibbs NM. Venous thrombosis of the lower limbs with particular reference to bed-rest. Br J Surg. 1957;45:209-235.
31. Warlow C, Ogston D, Douglas AS. Deep venous thrombosis of the legs after stroke. Br Med J. 1976;1:1178-1181.
32. Symington IS, Stack BHR. Pulmonary thromboembolism after travel. Br J Dis Chest. 1977;71:138-140.
33. Cruickshank JM, Gorlin R, Jennett B. Air travel and thrombotic episodes: the economy class syndrome. Lancet. 1988;ii:497-498.
34. Eschwege V, Robert A. Strikes in French public transport and resistance to activated protein C. Lancet. 1996;347:206.
35. Jordan WM. Pulmonary embolism. Lancet. 1961;ii:1146-1147.
36. Sartwell PE, Masi AT, Arthes FG, Greene GR, Smith HE. Thromboembolism and oral contraceptives: an epidemiological case-control study. Am J Epidemiol. 1969;90:365-380.
37. Stadel BV. Oral contraceptives and cardiovascular disease (first of two parts). N Engl J Med. 1981;305:612-618.
38. Inman WHW, Vessey MP. Investigation of death from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. Br Med J. 1968;193-199.
39. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. Br Med J. 1968;i:199-205.
40. Boston Collaborative Drug Surveillance Program. Oral contraceptives and venous thromboembolic disease, surgically confirmed gall bladder disease and breast tumours. Lancet. 1973;i:1399-1404.
41. Porter JB: Oral contraceptives and nonfatal vascular disease-recent experience. Obstet Gynecol. 1982;59:299-302.
42. World Health Organization. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346:1575-1582.
43. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research group on Oral Contraceptives and the Health of Young Women. BMJ. 1996;312:83-88.
44. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 1995;346:1593-1596.
45. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol. 1991;133:32-37.
46. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific group. WHO Technical Report Series, no. 877. Geneva, World Health Organization; 1998.
47. Bloemenkamp KWM, Rosendaal FR, Heimerhorst FM, Büller HR, Colly LP, Vandenbroucke JP. The association between oral contraceptives and venous thrombosis: the myth of the diagnostic suspicion- and referral bias. Arch Intern Med. 1999;159:65-70.
48. World Health Organization. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346:1582-1588.
49. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995;346:1589-1593.
50. Andersen BS, Olsen J, Nielsen GL, Steffensen FH, Sørensen HT, Baech J, Gregersen H. Third generation oral contraceptives and heritable thrombophilia as risk factors for non-fatal venous thromboembolism. Thromb Haemost. 1998;79:28-31.
51. Rosing J, Tans G, Nicolaes GA, Thomassen MC, Van Oerle R, Van der Ploeg PM, Heijen P, Hamulyak K, Hemker HC. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol. 1997;97:233-238.
52. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996;348:983-987.
53. Grady D, Furberg C. Venous thromboembolic events associated with hormone replacement therapy. JAMA. 1997;278:477-477.
54. Kierkegaard A. Incidence and diagnosis of deep vein thrombosis associated with pregnancy. Acta Obstet Gynecol Scand. 1983;62:239-243.
55. Treffers PE, Huidekoper BL, Weenink GH, Kloosterman GJ. Epidemiological observations of thromboembolic disease during pregnancy and in the puerperium, in 56,022 women. Int J Gynaecol Obstet. 1983;21:327-331.
56. McColl MD, Ramsay JE, Tait RC, Walker JD, McCall F, Conkie JA, Carty MJ, Greer IA. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost. 1997;78:1183-1188.
57. Love PE, Santoro SE. Antiphospholipid antibodies: anticardiolipin antibodies and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med. 1990;112:682-698.
58. Fijnheer R, Horbach DA, Donders RCJM, Vilé H, van Oort E, Nieuwenhuis HK, Gmelig-Meijling FHJ, de Groot PhG, Derksen RHWM. Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus. Thromb Haemost. 1996;76:514-517.
59. Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, Stevens P, Hirsh J. Antiphospholipid antibodies and venous thromboembolism. Blood. 1995;86:3685-3691.
60. Simioni P, Prandoni P, Zanon E, Saracino MA, Scudeller A, Villalta S, Scarano L, Girolami B, Benedetti L, Girolami A. Deep venous thrombosis and lupus anticoagulant. Thromb Haemost. 1996;76:187-189.
61. Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J, the EMET Group. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism-results of the Spanish multicentric study on thrombophilia (EMET-study). Thromb Haemost. 1997;77:444-451.
62. Halbmayer WM, HaushoferA, Schon R, Mannhalter C, Strohmer E, Baumgarten K, Fischer M. The prevalence of moderate and severe FXII (Hageman factor) deficiency among the normal population: evaluation of the incidence of FXII deficiency among 300 healthy blood donors. Thromb Haemost. 1994;71:68-72.
63. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981; 68:1370-1373.
64. Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism: a study of three Dutch families. N Engl J Med. 1983;309:340-344.
65. Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briët E. Increased risk of venous thrombosis in carriers of protein C deficiency defect. Lancet. 1993;341:134-138.
66. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. APC-resistance as an additional risk factor for thrombosis in protein C deficient families. Blood. 1994;84:1031-1035.
67. Heijboer H, Brandjes DPM, Büller HR, Sturk A, Ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 1990;323:1512-1516.
68. Koster T, Rosendaal FR, Briët E, Van der Meer FJM, Colly LP, Trienekens PH, Poort SR, Vandenbroucke JP. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 1995;85:2756-2761.
69. Tait RC, Walker ID, Reitsma PH, Islam SI, McCall F, Poort SR, Conkie JA, Bertina RM. Prevalence of protein C deficiency in the healthy population. Thromb Haemost. 1995;73:87-93.
70. Schwarz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasma protein S deficiency in familial thrombotic disease. Blood. 1984;64:1297-1300.
71. Simmonds RE, Ireland H, Lane DA, Zöller B, García de Frutos P, Dahlbäck B. Clarification of the risk for venous thrombosis associated with hereditary protein S deficiency by investigation of a large kindred with a characterized gene defect. Ann Intern Med. 1998;128:8-14.
72. Zöller B, Garcia de Frutos P, Dahlbäck B. Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood. 1995;85:3524-3531.
73. Simmonds RE, Zöller B, Ireland H, Thompson E, García de Frutos P, Dahlbäck B, Lane DA. Genetic and phenotypic analysis of a large (122-member) protein S-deficient kindred provides an explanation for the familial coexistence of type I and type III plasma phenotypes. Blood. 1997;89:4364-4370.
74. Faioni EM, Valsecchi C, Palla A, Taioli E, Razzari C, Mannucci PM. Free protein S deficiency is a risk factor for venous thrombosis. Thromb Haemost. 1997;78:1343-1346.
75. Koeleman BPC, Van Rumpt D, Hamulyak K, Reitsma PH, Beitina RM. Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families? Thromb Haemost. 1995;74:580-583.
76. Zöller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood. 1995;85:3518-3523.
77. Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol. 1981;10:369-390.
78. Demers C, Ginsberg JS, Hirsh J, Henderson P, Blajchman MA. Thrombosis in antithrombin III-deficient persons: report of a large kindred and literature review. Ann Intern Med. 1992;116:754-761.
79. Hirsh J, Piovella F , Pini M. Congenital antithrombin III deficiency: incidence and clinical features. Am J Med. 1989;87(Suppl):34-38.
80. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited Thrombophilia: Part 1. Thromb Haemost. 1996;76:651-662.
81. Van Boven HH, Reitsma PH, Rosendaal FR, Bayston TA, Chowdhury V, Bauer KA, Scharrer I, Conard J, Lane DA. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost. 1996;75:417-421.
82. Tait RC, Walker ID, Perry DJ, Islam SI, Daly ME, McCall F, Conkie JA, Carrell RW. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol. 1994;87:106-112.
83. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346:1133-1134.
84. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504-1508.
85. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. JAMA. 1997;277:1305-1307.
86. Bertina RM, Koeleman RPC, Koster T, Rosendaal FR, Dirven RJ, De Ronde H, Van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
87. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90:1004-1008.
88. Koster T, Rosendaal FR, De Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to a poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993;342:1503-1506.
89. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-917.
90. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood. 1993;82:1989-1993.
91. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
92. Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CRM. The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population. Br J Haematol. 1997;98:353-355.
93. Hillarp A, Zöller B, Svensson PJ, Dahlbäck B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost. 1997;78:990-992.
94. Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′ untranslated region of the prothrombin gene. Br J Haematol. 1997;98:907-909.
95. Rosendaal FR, Doggen CJM, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998;79:706-708.
96. Souto JC, Coll I, Llobet D, del Río E, Oliver A, Mateo J, Borrell M, Fontcuberta J. The prothrombin 20210A allele is the most present genetic risk factor for venous thromboembolism in the Spanish population. Thromb Haemost. 1998;80:366-369.
97. Jick H, Slone D, Westerholm B, Inman WHW, Vessey MP, Shapiro S, Lewis GP, Worcester J. Venous thromboembolic disease and ABO blood type. Lancet. 1969;i:539-542.
98. Jick H, Porter J. Thrombophlebitis of the lower extremities and ABO blood type. Arch Intern Med. 1978;138:1566-1567.
99. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152-155.
100. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood groups on the diagnosis of von Willebrand disease. Blood. 1987;69:1691-1695.
101. Weis HJ, Sussman I, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. J Clin Invest. 1997;60:390-404.
102. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb. 1994;14:1080-1083.
103. Den Heijer M, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759-762.
104. Simioni P, Prandoni P, Burlina A, Tormene D, Sardella C, Ferrari V, Benedetti L, Girolami A. Hyperhomocysteinemia and deep-vein thrombosis: a case-control study. Thromb Haemost. 1996;76:883-886.
105. Den Heijer M, Rosendaal FR, Blom HJ, Gerrits WBJ, Bos GMJ. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost. 1998;80:874-877.
106. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood. 1997;90:1-11.
107. Kang SS, Wong PWK, Norusis M. Homocysteinemia due to folate deficiency. Metabolism. 1987;36:458-462.
108. Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thrombosis Research. 1993;71:337-359.
109. Ubbink JB, Vermaak WJ, Van der Merwe A, Becker PJ. Vitamin B12, vitamin B6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr. 1993;57:47-53.
110. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wikken B, Pyeritz RE, Andria G, Boers GH, Bromberg IL, Cerone R. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985;37:1-31.
111. Engbertsen AMT, Franken DG, Boers GHJ, Stevens EMB, Trijbels FJM, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet. 1995;56:142-150.
112. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GHJ, Den Heijer M, Kluijtmans LAJ, Van den Heuvel LPWJ, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
113. Kang SS, Zhou J, Wong PWK, Kowlisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet. 1988;48:536-545.
114. Kluijtmans LAJ, Den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrpfolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost. 1998;254-258.
115. Queré I, Chasse JF, Dupuy E, Bellet E, Molho-Sabatier P, Tobelem G, Janbon C. Homocysteine, 5,10-methylenetetrahydrofolate reductase et thrombose veneuse profonde. Enquête aupres de 120 patients en médécine interne. Rev Med Interne. 1998;19:29-33.
116. Margaglione M, D'Andrea G, d'Addedda M, Giuliani N, Cappucci G, Iannaccone L, Vecchione G, Grandone E, Brancaccio V, Di Minno G: The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation. Thromb Haemost. 1998;79:907-911.
117. O'Donnell J, Tuddenham EGD, Manning R, Kemball-Cook G, Johnson D, Laffan M: High prevalence of elevated FVIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost. 1997;77:825-828.(Abstract)
118. Kamphuisen PW, Houwing-Duistermaat JJ, van Houwelingen JC, Eikenboom JCJ, Bertina RM, Rosendaal FR. Familial clustering of factor VIII and von Willebrand factor levels. Thromb Haemost. 1998;79:323-327.
119. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor v gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994;94:2521-2524.
120. Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost. 1995;74:449-453.
121. de Visser MCH, Rosendaal FR, Bertina RM: A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999;93:1271-1276.
122. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306→Thr) associated with resistance to activated protein C. Blood. 1998;91:1140-1144.
123. Olivieri O, Friso S, Manzato F, Guella A, Bernardi F, Lunghi B, Girelli D, Azzini M, Brocco G, Russo C. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995;91:465-470.
124. Cumming AM, Tait RC, Fildes S, Yoong A, Keeney S, Hay CR. Development of resistance to activated protein C during pregnancy. Br J Haematol. 1995;90:725-727.